This Medtech Stock Is Trading at a Discount to Peers. BTIG Says It's a Buy

Why It Matters

The upgrade signals that Medtronic’s undervalued stock and new product pipeline could deliver meaningful returns, reinforcing its position in a growing medtech market.

Key Takeaways

• Medtronic trades at 13× forward earnings vs 16.6× peer average
• BTIG upgrades Medtronic to Buy with $90 price target, 15% upside
• New FDA‑approved Altaviva and Symplicity products expected to drive growth
• Shares down about 19% YTD despite decade‑long revenue peak
• Half of analysts rate Medtronic Buy or Strong‑Buy, supporting upgrade

Pulse Analysis

Medtronic (MDT) remains the largest player in the global medical‑technology market, yet its stock trades at a noticeable discount to comparable firms. At roughly 13 times forward earnings, the company is undervalued against a peer average of 16.6 times, according to FactSet data. The valuation gap reflects a market that has under‑appreciated Medtronic’s durable cash flow and the resilience of its product portfolio. BTIG’s recent upgrade to “Buy” underscores the belief that the price gap offers a clear entry point for long‑term investors.

The upgrade is anchored in concrete growth drivers, most notably the launch of two FDA‑cleared therapies. Altaviva, an implantable device for urinary incontinence, expands Medtronic’s urology franchise, while Symplicity, a catheter‑based renal denervation system, targets resistant hypertension—a condition affecting millions of Americans. Both products have already begun generating incremental revenue and are projected to scale as physicians adopt them. The therapies also align with rising demand for minimally invasive solutions, further enhancing reimbursement prospects. Coupled with a 10‑year revenue high in fiscal 2026, the firm’s organic top‑line momentum suggests a sustainable earnings trajectory.

Analyst consensus reinforces the bullish outlook: 18 of 33 coverage analysts rate the stock as Buy or Strong‑Buy, and the $90 price target implies roughly 15 percent upside from the current price. Despite a 19 percent decline year‑to‑date, the dip creates a margin of safety for investors seeking exposure to a sector poised for aging‑population growth. Risks remain, including potential reimbursement pressure and competitive innovation cycles, but the combination of valuation headroom, pipeline strength, and broad analyst support positions Medtronic as a compelling addition to a diversified healthcare portfolio.